Evidence presented at the House of Lords showed that multiple targets, with multi combination medicinal products are extremely effective. This could be a turning point for researchers focusing on single gene targets for specific diseases as the concept is similar to the popular polypill in cardiovascular medicine but by delivering a resolution to disease without unwanted side effects.
Dr Alta Smit of Biologische Heilmittel Heel GmbH showed convincing evidence that recent shifts in scientific thinking have moved experts to concentrate on the complexity of diseases for finding safe and effective solutions instead of placing their focus on reducing single targets as was the case previously.
Many chronic diseases, for example cancer, Alzheimer’s and cardiovascular disease share a common denominator: chronic inflammation. However, because the acute inflammatory process is one of the body’s primary defense mechanisms, upsetting this fine balance with current anti-inflammatory interventions can therefore result in progression of the disease rather than its cure.
Dr. Smit stated that the ideal treatment is therefore not to suppress the acute inflammatory process but to support every phase of disease resolution by allowing the body to heal naturally. She presented data, which revealed that low dose multi-combination preparations affect multiple gene targets, which results in a significantly positive outcome on the inflammatory network after just 3 hours.
‘Bioregulating medicines’ therefore treat conditions by taking the body’s own natural auto-regulatory systems into account in order to restore disease-induced disturbances without interfering with vital self-regulatory defense mechanisms.
Although homeopathic medicines have been used for hundreds of years, scientists have revealed the real value of bioregulatory medicine by using new genomic tests using today’s technology.
Dr Peter Fisher, Physician to Her Majesty The Queen and Clinical Director at the Royal London Hospital for Integrated Medicine commented:
“Despite controversy, homeopathic medicine is growing in reputation and recognition amongst the public and clinicians. This is mainly due to its ‘whole person’ healing effects and lack of the side effects associated with conventional pharmaceutical treatments especially when they involve polypharmacy.”
Roger Wilson, Managing Director of Bio Pathica added:
“Bio Pathica are fully committed to supporting and publicizing the science behind the solutions. The evidence shows that by designing disease solutions that work with the body and not against it will significantly reduce the problems of drug side effects”.
The importance of this research could be significant; it could enable a seamless integration of bioregulatory medicines with traditional pharmaceuticals allowing clinicians to treat patients ‘as a whole’ and not simply as a series of symptoms.
Written by Petra Rattue